MASI, PLRX and CGC Are Among After Hour Movers

Seeking AlphaMar 22 16:59 ET

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)

TipRanksMar 13 07:11 ET

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)

TipRanksMar 12 12:50 ET

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m

Simply Wall StMar 6 05:10 ET

Pliant Therapeutics Price Target Raised to $54.00/Share From $50.00 by RBC Capital

Pliant Therapeutics Price Target Raised to $54.00/Share From $50.00 by RBC Capital

Dow JonesMar 5 10:37 ET

RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept

Pliant Therapeutics (PLRX) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $33 to $54. Price: 16.6, Change: +0.21, Percent Change: +1.28

MT NewswiresMar 5 07:57 ET